School of Medicine


Showing 1-50 of 163 Results

  • Ranjana Advani

    Ranjana Advani

    Saul A. Rosenberg, MD, Professor of Lymphoma

    Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

    The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

  • Ash A. Alizadeh, MD/PhD

    Ash A. Alizadeh, MD/PhD

    Moghadam Family Professor

    Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

    Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

  • Xiangqi Bai

    Xiangqi Bai

    Postdoctoral Scholar, Oncology

    BioMy research is focused on computational and systems biology. My primary research interest lies in developing new computational algorithms and statistical methods for the analysis of complex data in biological systems, especially related to the large-scale single-cell RNA sequencing data. The specific topics I have examined include:
    1. Integration of single-cell multi-omics datasets for tumor
    2. Statistical test of cell developmental trajectories
    3. Visualization and reconstruction of single-cell RNA sequencing data
    4. Computational analysis of the bifurcating event revealed by dynamical network biomarker methods

  • Allison Betof Warner, MD, PhD

    Allison Betof Warner, MD, PhD

    Assistant Professor of Medicine (Oncology)

    BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.

    Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.

    Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.

    Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.

  • Douglas W. Blayney

    Douglas W. Blayney

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally

  • Nam Quoc Bui

    Nam Quoc Bui

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.

    His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to students and trainees. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer.

  • M. Gohazrua K.  Butler

    M. Gohazrua K. Butler

    Temp - Non-Exempt, Medicine - Med/Oncology

    Current Role at StanfordTeaching Assistant - Master of Science in Translational Research and Applied Medicine

  • Robert W. Carlson

    Robert W. Carlson

    Professor of Medicine (Oncology and General Internal Medicine/Medical Informatics) at the Stanford University Medical Center, Emeritus

    Current Research and Scholarly InterestsClinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.

  • Jennifer Caswell-Jin

    Jennifer Caswell-Jin

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMy research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.

  • Amina Chaudhry, MD

    Amina Chaudhry, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Amina Chaudhry is a medical oncologist in the Division of Oncology at Stanford University School of Medicine. As part of Stanford University’s Breast Cancer Program, she specializes in treating patients diagnosed with breast cancer.

    Dr. Chaudhry completed a residency in internal medicine at the University of Tennessee Health Science Center. She gained advanced training in hematology and oncology through a fellowship at University of Illinois Chicago. She is certified by the American Board of Internal Medicine.

    Dr. Chaudhry’s research focuses on improving outcomes in disadvantaged populations with breast cancer. In 2022, she received the Repurposing Research to Address Diversity, Equity, and Inclusion grant to support underrepresented patients with early-stage breast cancer.

    Dr. Chaudhry has published research in journals including Annals of Oncology, Journal of Clinical Oncology, and Blood Advances. She has presented her work at the annual meetings of the American Society of Clinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH).

    Dr. Chaudhry has a strong interest in tackling healthcare inequities and improving access to clinical trials.

  • Christopher T Chen, MD

    Christopher T Chen, MD

    Assistant Professor of Medicine (Oncology)

    BioDr. Chen is a board-certified, fellowship-trained specialist in oncology and hematology. He is also an Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

    Dr. Chen delivers comprehensive, compassionate care for patients in need of early drug development clinical trials and patients with gastrointestinal cancers. As a researcher, he leads the early drug development group and studies how tumor heterogeneity limits the clinical benefit of anticancer therapies in order to accelerate development of novel therapeutic strategies. Dr. Chen’s work has appeared in the New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Science Advances, Journal of Oncology Practice, and Health Services Research.

    Dr. Chen attended Harvard College, where he graduated summa cum laude and Phi Beta Kappa in molecular biology. He went to medical school at Washington University in St. Louis on a full-tuition merit scholarship, graduating with Alpha Omega Alpha honors, and did his residency training in internal medicine at Massachusetts General Hospital and hematology/oncology fellowship in the combined Harvard Dana-Farber Cancer Institute/Massachusetts General Hospital program. As a fellow, he received the NIH T-32 Ruth L. Kirchstein-National Service Research Award in Cancer Biology for his work exploring the molecular structure of metastatic solid tumors.

    Dr. Chen is a member of the American Society of Clinical Oncology, European Society for Medical Oncology, and American Association for Cancer Research.

  • Tianqi Chen

    Tianqi Chen

    Postdoctoral Scholar, Oncology

    BioMy research interest lies in liquid biopsy and early cancer diagnostics, e.g. development of bioassay for detection of cancer biomarkers (proteins and genes) and single-cell research. As well as the integration of 3D-printed microfluidics.

  • Curtis R. Chong, MD, PhD, MPhil, FACP

    Curtis R. Chong, MD, PhD, MPhil, FACP

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Chong was recruited to Stanford from the Memorial Sloan Kettering (MSK) Cancer Center, where he led MSK's launch of the early drug development and immunotherapy clinical trials program in New Jersey. At MSK, Dr. Chong was a member of the gastrointestinal oncology service and was one of two MSK physicians in New Jersey who specialized in treating melanoma. Prior to joining MSK, Dr. Chong was a member of the thoracic oncology service at the Dana-Farber Cancer Institute and an attending physician at the Massachusetts General Hospital and Brigham and Women's Hospital, all ailiates of Harvard Medical School.

    Dr. Chong completed his categorical residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, his oncology fellowship at the Dana-Farber Cancer Institute, and is board-certified in internal medicine and medical oncology. He has received research support from the American Society of Clinical Oncology (Young Investigator Award), Uniting Against Lung Cancer, and the American Cancer Society. Dr. Chong has been published in the New England Journal of Medicine, Nature, Nature Medicine, Nature Chemical Biology, JAMA Oncology, and his research on drug discovery has been featured in the New York Times and Popular Science.

    Born and raised in Honolulu where he attended public schools, Dr. Chong sang in the Honolulu Boy Choir, and was the 1993 Honolulu Star Bulletin Newspaper Boy of the Year. He received his A.B. in biochemical sciences from Harvard University magna cum laude followed by an M.Phil. in Chemistry with Sir Alan Fersht at the University of Cambridge (Emmanuel College). He then received his MD and PhD in pharmacology from The Johns Hopkins University School of Medicine.

    An intrepid traveler and avid long-distance runner, Dr. Chong has visited 54 countries and completed 126 marathons in all 50 states, 18 countries, and 6 on continents.

  • Gilbert Chu

    Gilbert Chu

    Professor of Medicine (Oncology) and of Biochemistry

    Current Research and Scholarly InterestsAfter shuttering the wet lab, we have focused on: a point-of-care device to measure blood ammonia and prevent brain damage; a human protein complex that juxtaposes and joins DNA ends for repair and V(D)J recombination; and strategies for teaching students and for reducing selection bias in educational programs.

  • Michael F. Clarke, M.D.

    Michael F. Clarke, M.D.

    Karel H. and Avice N. Beekhuis Professor of Cancer Biology

    Current Research and Scholarly InterestsDr. Clarke maintains a laboratory focused on two areas of research: i) the control of self-renewal of normal stem cells and diseases such as cancer and hereditary diseases; and ii) the identification and characterization of cancer stem cells. His laboratory is investigating how perturbations of stem cell regulatory machinery contributes to human disease. In particular, the laboratory is investigating epigenetic regulators of self renewal, the process by which stem cells regenerate themselves.

  • Steven M. Corsello

    Steven M. Corsello

    Assistant Professor of Medicine (Oncology) and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsOur laboratory operates at the intersection of functional genomics and chemical biology, with the goal of advancing novel molecular mechanisms of cancer inhibition to clinical use. We aim to 1) leverage phenotypic screening and functional genomics to determine novel anti-cancer mechanisms of small molecules, 2) develop new targeted therapy approaches against solid tumors, and 3) build a comprehensive community resource for drug repurposing discovery.

  • Christina Curtis

    Christina Curtis

    RZ Cao Professor, Professor of Genetics and of Biomedical Data Science

    Current Research and Scholarly InterestsThe Curtis laboratory for Cancer Computational and Systems Biology is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.

  • Millie Das

    Millie Das

    Clinical Professor, Medicine - Oncology

    BioDr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.

  • Milana V. Dolezal, MD, MSci

    Milana V. Dolezal, MD, MSci

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology.

    She strives to work with patients to develop care plans that are comprehensive and personalized achieve the best possible outcomes and quality of life.

    Dr. Dolezal also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech.

    She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients’ adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications.

    She also co-authored the chapter “Progression from Hormone-Dependent to Hormone-Independent Breast Cancer” in the textbook Hormones, Genes and Cancer published by Oxford University Press.

    Dr. Dolezal has made presentations to her peers at meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Organisation.

  • George Duran

    George Duran

    Cancer Biologist and Laboratory Manager, Medicine - Med/Oncology

    Current Role at StanfordCancer biologist specializing in the development of novel chemotherapeutic agents and in mechanisms of drug resistance. Current research ranges from molecular studies to further understand the heterogeneity of T-cell lymphomas, to translational studies of molecular determinants of therapeutic response, and clinical trials that use the body’s immune system to fight cancer cells.

    Original research contributions have resulted in the authorship of over eighty publications.

  • Alice C. Fan

    Alice C. Fan

    Associate Professor of Medicine (Oncology) and, by courtesy, of Urology

    Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.

  • Dean W. Felsher

    Dean W. Felsher

    Professor of Medicine (Oncology) and of Pathology

    Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.

  • George A. Fisher Jr.

    George A. Fisher Jr.

    Colleen Haas Chair in the School of Medicine

    Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

  • James Ford

    James Ford

    Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.

  • Kristen N Ganjoo

    Kristen N Ganjoo

    Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsGiant cell tumor of the bone
    Gastrointestinal stromal tumors
    Soft tissue sarcoma
    Osteosarcoma